Boston Scientific’s coronary IVL catheter hits primary endpoints in trial

Boston Scientific plans to use the IDE trials results to support a regulatory filing of its Seismiq 4CE Coronary catheter with the FDA. Boston Scientific plans to use the IDE trials results to support a regulatory filing of its Seismiq 4CE Coronary catheter with the FDA. Since J&J’s acquisition of Shockwave Medical in June 2024, other big medtech players are gaining a foothold in the space. Credit: Michael Vi / Shutterstock Boston Scientific has shared positive pivotal trial results for its SEISMIQ 4CE Coronary intravascular lithotripsy (IVL) catheter in treating calcified coronary artery disease (CAD). The 420-patient FRACTURE trial (NCT06181240)…

Source: Clinical Trials Arena